No Data
No Data
Wanfu Biotech: Report for the first quarter of 2025
Guangzhou Wondfo Biotech (300482.SZ): In the first quarter, the net income was 0.189 billion yuan, a year-on-year decrease of 13.37%.
Gelonghui, April 24丨Guangzhou Wondfo Biotech (300482.SZ) announced its Q1 2025 report, with revenue of 0.8 billion yuan, a decrease of 7.06% year-on-year; Net income attributable to shareholders of the listed company was 0.189 billion yuan, down 13.37% year-on-year; Net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.172 billion yuan, down 17.57% year-on-year; EPS was 0.39 yuan.
We Think That There Are Some Issues For Guangzhou Wondfo BiotechLtd (SZSE:300482) Beyond Its Promising Earnings
Guangzhou Wondfo Biotech: Expanding business in developing countries to hedge risks in the US market | Directly addressing the Earnings Conference.
① Guangzhou Wondfo Biotech responded in the Earnings Conference that the expansion of Business in developing countries and the growth of domestic Business can effectively hedge against potential risks in the USA Business. ② Wang Jihua believes that starting in 2024, the domestic POCT market will stabilize and recover.
Guangzhou Wondfo Biotech Co.,Ltd Just Missed EPS By 11%: Here's What Analysts Think Will Happen Next
Insufficient Growth At Guangzhou Wondfo Biotech Co.,Ltd (SZSE:300482) Hampers Share Price